Characterization and real-live results of nebulized voriconazole: A single-center observational study
CONCLUSION: Voriconazole nebulization is well-tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.PMID:37612182 | DOI:10.1016/j.farma.2023.07.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Maria Larrosa-Garcia S ònia Terradas Campanario Aurora Fern ández Polo Carme Ca ñete Ramírez Alba Pau Parra David Campany Herrero Source Type: research
Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease
Farm Hosp. 2023 Aug 21:S1130-6343(23)00090-9. doi: 10.1016/j.farma.2023.06.015. Online ahead of print.NO ABSTRACTPMID:37612183 | DOI:10.1016/j.farma.2023.06.015 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Cristo Yared P érez Martin Jos é Ramón Alberto Alonso Jenifer Gonz ález Chávez Mar ía Pilar Díaz Ruiz Marta Su árez González Javier Merino Alonso Source Type: research
Current situation and evolution of the availability of drugs in the paediatric population in Spain
CONCLUSIONS: Drugs with authorised indications are increasingly available in the paediatric population and the trend is to extend the indication of authorised drugs to the adult population. However, barriers in terms of financing and marketing need to be expedited and overcome to facilitate access to them.PMID:37612184 | DOI:10.1016/j.farma.2023.07.014 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Juan Diego Paradas-Palomo Luc ía Yunquera-Romero Carmen Gallego-Fern ández Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy
CONCLUSIONS: The present study reports supratherapeutic concentrations of eculizumab in patients with aHUS, and defines higher concentrations than those described in the data sheet to achieve blockade, thus encouraging the personalization of treatment with eculizumab.PMID:37612186 | DOI:10.1016/j.farma.2023.07.009 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Alba Pau Parra Natalia Ramos Janire Perurena-Prieto Silvia Manrique-Rodr íguez Monica Climente Laura Garc ía Quintanilla Ángel Escolano Marta Miarons en nombre del grupo PK-ECU-ORPHAR Source Type: research
Characterization and real-live results of nebulized voriconazole: A single-center observational study
CONCLUSION: Voriconazole nebulization is well-tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.PMID:37612182 | DOI:10.1016/j.farma.2023.07.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Maria Larrosa-Garcia S ònia Terradas Campanario Aurora Fern ández Polo Carme Ca ñete Ramírez Alba Pau Parra David Campany Herrero Source Type: research
Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease
Farm Hosp. 2023 Aug 21:S1130-6343(23)00090-9. doi: 10.1016/j.farma.2023.06.015. Online ahead of print.NO ABSTRACTPMID:37612183 | DOI:10.1016/j.farma.2023.06.015 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Cristo Yared P érez Martin Jos é Ramón Alberto Alonso Jenifer Gonz ález Chávez Mar ía Pilar Díaz Ruiz Marta Su árez González Javier Merino Alonso Source Type: research
Current situation and evolution of the availability of drugs in the paediatric population in Spain
CONCLUSIONS: Drugs with authorised indications are increasingly available in the paediatric population and the trend is to extend the indication of authorised drugs to the adult population. However, barriers in terms of financing and marketing need to be expedited and overcome to facilitate access to them.PMID:37612184 | DOI:10.1016/j.farma.2023.07.014 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Juan Diego Paradas-Palomo Luc ía Yunquera-Romero Carmen Gallego-Fern ández Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy
CONCLUSIONS: The present study reports supratherapeutic concentrations of eculizumab in patients with aHUS, and defines higher concentrations than those described in the data sheet to achieve blockade, thus encouraging the personalization of treatment with eculizumab.PMID:37612186 | DOI:10.1016/j.farma.2023.07.009 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Alba Pau Parra Natalia Ramos Janire Perurena-Prieto Silvia Manrique-Rodr íguez Monica Climente Laura Garc ía Quintanilla Ángel Escolano Marta Miarons en nombre del grupo PK-ECU-ORPHAR Source Type: research
Characterization and real-live results of nebulized voriconazole: A single-center observational study
CONCLUSION: Voriconazole nebulization is well-tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.PMID:37612182 | DOI:10.1016/j.farma.2023.07.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Maria Larrosa-Garcia S ònia Terradas Campanario Aurora Fern ández Polo Carme Ca ñete Ramírez Alba Pau Parra David Campany Herrero Source Type: research
Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease
Farm Hosp. 2023 Aug 21:S1130-6343(23)00090-9. doi: 10.1016/j.farma.2023.06.015. Online ahead of print.NO ABSTRACTPMID:37612183 | DOI:10.1016/j.farma.2023.06.015 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Cristo Yared P érez Martin Jos é Ramón Alberto Alonso Jenifer Gonz ález Chávez Mar ía Pilar Díaz Ruiz Marta Su árez González Javier Merino Alonso Source Type: research
Current situation and evolution of the availability of drugs in the paediatric population in Spain
CONCLUSIONS: Drugs with authorised indications are increasingly available in the paediatric population and the trend is to extend the indication of authorised drugs to the adult population. However, barriers in terms of financing and marketing need to be expedited and overcome to facilitate access to them.PMID:37612184 | DOI:10.1016/j.farma.2023.07.014 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Juan Diego Paradas-Palomo Luc ía Yunquera-Romero Carmen Gallego-Fern ández Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy
CONCLUSIONS: The present study reports supratherapeutic concentrations of eculizumab in patients with aHUS, and defines higher concentrations than those described in the data sheet to achieve blockade, thus encouraging the personalization of treatment with eculizumab.PMID:37612186 | DOI:10.1016/j.farma.2023.07.009 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Alba Pau Parra Natalia Ramos Janire Perurena-Prieto Silvia Manrique-Rodr íguez Monica Climente Laura Garc ía Quintanilla Ángel Escolano Marta Miarons en nombre del grupo PK-ECU-ORPHAR Source Type: research
